Authors: Castilleja, A Ward, NE O'Brian, CA Swearingen, B Swan, E Gillogly, MA Murray, JL Kudelka, AP Gershenson, DM Ioannides, CG

Citation: A. Castilleja et al., Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity, MOL C BIOCH, 217(1-2), 2001, pp. 21-33

Authors: Lee, TV Kim, DK Peoples, GE Castilleja, A Murray, JL Gershenson, DM Ioannides, CG

Citation: Tv. Lee et al., Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides, J INTERF CY, 20(4), 2000, pp. 391-401

Authors: Lee, TV Anderson, BW Peoples, GE Castilleja, A Murray, JL Gershenson, DM Ioannides, CG

Citation: Tv. Lee et al., Identification of activated tumor antigen-reactive CD8(+) cells in healthyindividuals, ONCOL REP, 7(3), 2000, pp. 455-466

Authors: Kim, DK Lee, TV Castilleja, A Anderson, BW Peoples, GE Kudelka, AP Murray, JL Sittisomwong, T Wharton, JT Kim, JW Ioannides, CG

Citation: Dk. Kim et al., Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients, ANTICANC R, 19(4B), 1999, pp. 2907-2916

Authors: Babcock, B Anderson, BW Papayannopoulos, I Castilleja, A Murray, JL Stifani, S Kudelka, AP Wharton, JT Ioannides, CG

Citation: B. Babcock et al., Ovarian and breast cytotoxic T lymphocytes can recognize peptides from theamino enhancer of split protein of the Notch complex, MOL IMMUNOL, 35(17), 1998, pp. 1121-1133